Skip to content Skip to footer
Subscribe Now
VIEWPOINTS

Unlocking Approval: Christophe Piketty from Galderma in an Illuminating Conversation with PharmaShots 

Shots:   Backed by positive results from the P-III ARCADIA study, Galderma’s Nemluvio recently received approval from the US FDA for patients with moderate to severe atopic dermatitis  Nemluvio (nemolizumab) has previously been approved for the treatment of prurigo nodularis  Christophe Piketty, VP, Head of Innovation, Therapeutic Dermatology, Global Clinical Sciences, Galderma, highlighted insights from the…
June 30, 2025

Read more

10 Hidden Financial Risks Pharma Professionals Can’t Ignore
THOUGHTSPOT

10 Hidden Financial Risks Pharma Professionals Can’t Ignore

Working in the pharmaceutical industry comes with great rewards—but it’s not without its financial blind spots. High income, stock options, consulting gigs, and regulatory risk make this a unique environment where professionals can be exposed without realizing it.  If you’re focused on research, development, or clinical work, it’s easy to overlook personal finance strategy. But…
June 30, 2025

Read more

The Evolving Role of Nurses in the Pharmaceutical Industry
THOUGHTSPOT

The Evolving Role of Nurses in the Pharmaceutical Industry

In today’s rapidly changing healthcare world, nurses are stepping into roles that go far beyond traditional bedside care. With the healthcare system becoming increasingly interconnected and innovation reshaping how care is delivered, new opportunities are emerging that allow nurses to use their clinical expertise in areas once reserved for scientists, researchers, and corporate professionals. One…
June 30, 2025

Read more

INSIGHTS+

Disease of the Month – Angina 

Shots:  Characterized by discomfort or pain in the chest, Angina develops when the heart does not receive adequate oxygen-rich blood  PharmaShots' Disease of the Month report aims to familiarize the general population with conditions impacting communities worldwide. The report outlines disease characteristics, types, symptoms, diagnosis, treatments, epidemiology, market size, clinical trial analysis, patient advocacy groups (PAGs),…
June 25, 2025

Read more

INSIGHTS+

New Drug Designations – May 2025  

Shots:      PharmaShots’ Designation Report provides a concise overview of the latest drug designations granted by major regulatory authorities, including the FDA, EMA, MHLW, Health Canada and NMPA    The May 2025 report covers designations granted to 44 drugs and 5 medical devices, spanning 15 small molecules, 7 biologics, 13 cell and gene therapies & 5 medical devices among others   …
June 24, 2025

Read more

THOUGHTSPOT

Precision Medicine in Cancer Treatment: Revolutionizing Patient Care Through Personalized Approaches

Precision medicine has emerged as a transformative approach in cancer treatment, moving away from the traditional one-size-fits-all methodology toward highly individualized therapeutic strategies. This paradigm shift recognizes that each patient's cancer is unique, with distinct genetic profiles, molecular characteristics, and treatment responses that require tailored approaches. By leveraging advanced genomic technologies, biomarker identification, and sophisticated…
June 24, 2025

Read more

Enhancing Hematologic Care: Lorah Perlee from Regeneron in a Riveting Dialogue Exchange with PharmaShots
VIEWPOINTS

Enhancing Hematologic Care: Lorah Perlee from Regeneron in a Riveting Dialogue Exchange with PharmaShots

Shots:  At ASH 2024, Regeneron shared data from the P-III exploratory cohort investigating the pozelimab and cemdisiran combination (poze-cemdi) in patients with paroxysmal nocturnal hemoglobinuria  The novel combination (poze-cemdi) achieved meaningful control of intravascular hemolysis compared to ravulizumab   PharmaShots welcomes Lorah Perlee, Vice President, Global Program Head, Hematology and Translational Sciences at Regeneron, for an…
June 23, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (Jun 16, 2025 – Jun 20, 2025)   

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilar, Animal Health & DigiHealth. Check out our full report below:    Johnson & Johnson Reports P-II (RedirecTT-1) Trial Data on Talvey + Tecvayli for R/R Multiple Myeloma  Read More: J&J  Camurus Reports Topline P-IIb (POSITANO) Trial Data on CAM2029 for…
June 20, 2025

Read more

TOP 20

Top 20 Nutraceutical Companies of 2025

Shots:  Nutraceuticals offer significant health benefits by enhancing body function and supporting body repair and growth  In 2024, the global nutraceuticals market is valued at $458.55B and is projected to rise to $986.85B by 2032, growing at a CAGR of 10.18%. Nestlé leads the market with reported segment revenue of $16.75B, followed by Danone and…
June 19, 2025

Read more

Load more